Page last updated: 2024-10-27

fluorouracil and Sensation Disorders

fluorouracil has been researched along with Sensation Disorders in 7 studies

Fluorouracil: A pyrimidine analog that is an antineoplastic antimetabolite. It interferes with DNA synthesis by blocking the THYMIDYLATE SYNTHETASE conversion of deoxyuridylic acid to thymidylic acid.
5-fluorouracil : A nucleobase analogue that is uracil in which the hydrogen at position 5 is replaced by fluorine. It is an antineoplastic agent which acts as an antimetabolite - following conversion to the active deoxynucleotide, it inhibits DNA synthesis (by blocking the conversion of deoxyuridylic acid to thymidylic acid by the cellular enzyme thymidylate synthetase) and so slows tumour growth.

Sensation Disorders: Disorders of the special senses (i.e., VISION; HEARING; TASTE; and SMELL) or somatosensory system (i.e., afferent components of the PERIPHERAL NERVOUS SYSTEM).

Research Excerpts

ExcerptRelevanceReference
"In a previous study of treatment for advanced colorectal cancer, the LV5FU2 regimen, comprising leucovorin (LV) plus bolus and infusional fluorouracil (5FU) every 2 weeks, was superior to the standard North Central Cancer Treatment Group/Mayo Clinic 5-day bolus 5FU/LV regimen."9.09Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. ( Bonetti, A; Boni, C; Cassidy, J; Cervantes, A; Cortes-Funes, H; de Braud, F; de Gramont, A; Figer, A; Freyer, G; Hendler, D; Hmissi, A; Homerin, M; Le Bail, N; Louvet, C; Morvan, F; Papamichael, D; Seymour, M; Wilson, C, 2000)
"Taxanes used in adjuvant therapy for breast cancer are neurotoxic, and thereby being a potential risk factor for persistent pain after breast cancer treatment (PPBCT) and sensory disturbances."5.38Persistent pain, sensory disturbances and functional impairment after adjuvant chemotherapy for breast cancer: cyclophosphamide, epirubicin and fluorouracil compared with docetaxel + epirubicin and cyclophosphamide. ( Andersen, KG; Eckhoff, L; Gärtner, R; Jensen, MB; Kehlet, H; Kroman, N, 2012)
"In a previous study of treatment for advanced colorectal cancer, the LV5FU2 regimen, comprising leucovorin (LV) plus bolus and infusional fluorouracil (5FU) every 2 weeks, was superior to the standard North Central Cancer Treatment Group/Mayo Clinic 5-day bolus 5FU/LV regimen."5.09Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. ( Bonetti, A; Boni, C; Cassidy, J; Cervantes, A; Cortes-Funes, H; de Braud, F; de Gramont, A; Figer, A; Freyer, G; Hendler, D; Hmissi, A; Homerin, M; Le Bail, N; Louvet, C; Morvan, F; Papamichael, D; Seymour, M; Wilson, C, 2000)
"There were no statistically significant neuropathy differences among the study arms as measured by the primary end point or additional measures of neuropathy, including clinician-determined measurement of the time to grade 2 neuropathy by using the National Cancer Institute Common Terminology Criteria for Adverse Events scale or an oxaliplatin-specific neuropathy scale."2.79Phase III randomized, placebo-controlled, double-blind study of intravenous calcium and magnesium to prevent oxaliplatin-induced sensory neurotoxicity (N08CB/Alliance). ( Atherton, P; Dakhil, SR; Fehrenbacher, L; Flynn, KA; Grothey, A; Lewis, GC; Loprinzi, CL; Qamar, R; Qin, R; Seisler, D, 2014)
"To determine the dose-limiting toxicity of CPT-11 in combination with oxaliplatin, and the maximal tolerated dose (MTD) and the recommended dose (RD) of CPT-11 using an every two weeks schedule."2.69Dose escalation of CPT-11 in combination with oxaliplatin using an every two weeks schedule: a phase I study in advanced gastrointestinal cancer patients. ( Cvitkovic, E; Di Palma, M; Goldwasser, F; Gross-Goupil, M; Marceau-Suissa, J; Misset, JL; Tigaud, JM; Wasserman, E; Yovine, A, 2000)
"Taxanes used in adjuvant therapy for breast cancer are neurotoxic, and thereby being a potential risk factor for persistent pain after breast cancer treatment (PPBCT) and sensory disturbances."1.38Persistent pain, sensory disturbances and functional impairment after adjuvant chemotherapy for breast cancer: cyclophosphamide, epirubicin and fluorouracil compared with docetaxel + epirubicin and cyclophosphamide. ( Andersen, KG; Eckhoff, L; Gärtner, R; Jensen, MB; Kehlet, H; Kroman, N, 2012)

Research

Studies (7)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's2 (28.57)29.6817
2010's5 (71.43)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Loprinzi, CL1
Qin, R1
Dakhil, SR1
Fehrenbacher, L1
Flynn, KA1
Atherton, P1
Seisler, D1
Qamar, R1
Lewis, GC1
Grothey, A1
Matsuo, K1
Higuchi, M1
Sasaki, Y1
Iwatsubo, S1
Wada, Y1
Hasegawa, K1
Shirakawa, A1
Mishima, K1
Iwasaki, K1
Fujiwara, M1
Nishino, H1
Doi, T1
Boku, N1
Kato, K1
Komatsu, Y1
Yamaguchi, K1
Muro, K1
Hamamoto, Y1
Sato, A1
Koizumi, W1
Mizunuma, N1
Takiuchi, H1
Park, SB1
Lin, CS1
Krishnan, AV1
Goldstein, D1
Friedlander, ML1
Kiernan, MC1
Andersen, KG1
Jensen, MB1
Kehlet, H1
Gärtner, R1
Eckhoff, L1
Kroman, N1
de Gramont, A1
Figer, A1
Seymour, M1
Homerin, M1
Hmissi, A1
Cassidy, J1
Boni, C1
Cortes-Funes, H1
Cervantes, A1
Freyer, G1
Papamichael, D1
Le Bail, N1
Louvet, C1
Hendler, D1
de Braud, F1
Wilson, C1
Morvan, F1
Bonetti, A1
Goldwasser, F1
Gross-Goupil, M1
Tigaud, JM1
Di Palma, M1
Marceau-Suissa, J1
Wasserman, E1
Yovine, A1
Misset, JL1
Cvitkovic, E1

Clinical Trials (7)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
A Phase III Randomized, Placebo-Controlled, Double-Blind Study of Intravenous Calcium/Magnesium in Two Different Versions to Prevent Oxaliplatin-Induced Sensory Neurotoxicity[NCT01099449]Phase 3362 participants (Actual)Interventional2010-06-30Completed
Vitro 3D Drug Sensitivity Detection of Micro Tumor (PTC) Combined With Tumor Whole Exon (WES) Sequencing Technology to Guide Postoperative Adjuvant Treatment Strategy and Prognosis of Colorectal Cancer[NCT05424692]200 participants (Anticipated)Interventional2021-09-01Recruiting
Prospective Randomized Phase III Study of Concurrent Capecitabine and Radiotherapy With or Without Oxaliplatin as Adjuvant Treatment for Stage II and III Rectal Cancer[NCT00714077]570 participants (Anticipated)Observational2008-04-30Recruiting
Phase 2 Prospective Randomized Double Blind Trial Comparing Metastasectomy Plus Sulindac Versus Metastasectomy Alone in Patients With Stage IV Colorectal Cancer[NCT01856322]Phase 23 participants (Actual)Interventional2013-04-30Terminated (stopped due to The trial was prematurely closed due to lack of accrual.)
Phase 1b Trial of 5-fluorouracil, Leucovorin, Irinotecan in Combination With Temozolomide (FLIRT) and Bevacizumab for the First-line Treatment of Patients With MGMT Silenced, Microsatellite Stable Metastatic Colorectal Cancer.[NCT04689347]Phase 118 participants (Anticipated)Interventional2021-01-01Recruiting
A Phase ll Study of Oxaliplatin, Capecitabine, and Bevacizumab in the Treatment of Metastatic Esophagogastric Adenocarcinomas[NCT00447330]Phase 260 participants (Actual)Interventional2007-02-28Completed
A Randomized, Placebo-controlled, Double-blind Multicenter Phase II Study to Investigate the Protectivity and Efficacy of Metformin Against Steatosis in Combination With FOLFIRI and Cetuximab in Subjects With First-line Palliative Treated, KRAS-Wild-Type,[NCT01523639]Phase 28 participants (Actual)Interventional2012-04-30Terminated (stopped due to Prematurely due to slow recruitment (07/08/2013). Newly defined study end=LPLV=05/11/2013. ABCSG guaranteed completed treatment period for ethical reasons.)
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

Area Under the Curve (AUC) of European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire of Chemotherapy-induced Peripheral Neuropathy (EORTC QLQ-CIPN20) Motor Neuropathy Subscale Scores

The oxaliplatin-induced motor neuropathy as repeatedly measured by the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire of Chemotherapy-induced peripheral neuropathy (EORTC QLQ-CIPN20) motor neuropathy subscale during the chemotherapy. This is a multivariate repeated measurement of CIPN with possibly variable cycles for every patient. The CIPN motor neuropathy subscale will be calculated by standard scoring algorithm and converted to 0-100 scale, where higher scores represent a higher quality of life. Rather than choosing the CIPN20 motor neuropathy subscale at a fixed cycle of chemotherapy, we will adopt a summary measure, area under the curve (AUC) of CIPN20 motor neuropathy subscale as the endpoint. This AUC will be prorated by the number of chemotherapy cycles patients received. (NCT01099449)
Timeframe: Up to 18 Months

InterventionAUC QLQ-CIPN20 Motor Neuropathy Score (Mean)
Calcium Gluconate + Magnesium Sulfate (Pre and Post)94.1
Placebo (Pre and Post)93.3
Calcium Gluconate + Magnesium Sulfate (Pre), Placebo (Post)91.6

Area Under the Curve (AUC) of the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire of Chemotherapy-induced Peripheral Neuropathy (EORTC QLQ-CIPN20) Autonomic Neuropathy Subscale Scores

The oxaliplatin-induced autonomic neuropathy as repeatedly measured by the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire of Chemotherapy-induced peripheral neuropathy (EORTC QLQ-CIPN20) autonomic subscale during the chemotherapy. This is a multivariate repeated measurement of CIPN with possibly variable cycles for every patient. The CIPN autonomic subscale will be calculated by standard scoring algorithm and converted to 0-100 scale, where higher scores represent a higher quality of life. Rather than choosing the CIPN20 autonomic subscale at a fixed cycle of chemotherapy, we will adopt a summary measure, area under the curve (AUC) of CIPN20 autonomic subscale as the endpoint. This AUC will be prorated by the number of chemotherapy cycles patients received. (NCT01099449)
Timeframe: Up to 18 months

Interventionscore on a scale (Mean)
Calcium Gluconate + Magnesium Sulfate (Pre and Post)89.8
Placebo (Pre and Post)86.7
Calcium Gluconate + Magnesium Sulfate (Pre), Placebo (Post)84.5

Cumulative Oxaliplatin Doses That Can be Administered Without Dose-limiting Chronic Neurotoxicity

A patient has a dose-limiting chronic neurotoxicity when they discontinue oxaliplatin-based chemotherapy because of neurotoxicity. (NCT01099449)
Timeframe: Up to 18 months

InterventionDoses (Mean)
Calcium Gluconate + Magnesium Sulfate (Pre and Post)8.1
Placebo (Pre and Post)8.4
Calcium Gluconate + Magnesium Sulfate (Pre), Placebo (Post)8.0

Incidence of Calcium Gluconate and Magnesium Sulfate-induced Adverse Events as Measured by CTCAE Version 4.0

(NCT01099449)
Timeframe: Up to 18 months

InterventionNumber of reported Adverse Events (Number)
Arm I290
Arm II259
Arm III296

Percentage of Patients Discontinuing Oxaliplatin-based Chemotherapy Because of Neurotoxicity

(NCT01099449)
Timeframe: Up to 18 months

Interventionpercentage of patients (Number)
Calcium Gluconate + Magnesium Sulfate (Pre and Post)34.7
Placebo (Pre and Post)27.7
Calcium Gluconate + Magnesium Sulfate (Pre), Placebo (Post)30.5

Sensory Area Under the Curve(AUC) Score. Oxaliplatin-induced Sensory Neuropathy as Repeatedly Measured by the EORTC QLQ-CIPN20 Sensory Subscale During Chemotherapy

The oxaliplatin-induced sensory neuropathy as repeatedly measured by the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire of Chemotherapy-induced peripheral neuropathy (EORTC QLQ-CIPN20) sensory subscale during the chemotherapy. This is a multivariate repeated measurement of CIPN with possibly variable cycles for every patient. The CIPN sensory subscale will be calculated by standard scoring algorithm and converted to 0-100 scale, where higher scores represent a higher quality of life. Rather than choosing the CIPN20 sensory subscale at a fixed cycle of chemotherapy, we will adopt a summary measure, area under the curve (AUC) of CIPN20 sensory subscale as the primary endpoint. This AUC will be prorated by the number of chemotherapy cycles patients received. (NCT01099449)
Timeframe: Up to 18 months

Interventionscore on a scale (Mean)
Calcium Gluconate + Magnesium Sulfate (Pre and Post)89.2
Placebo (Pre and Post)88.3
Calcium Gluconate + Magnesium Sulfate (Pre), Placebo (Post)87.1

Area Under the Curve (AUC) of Patient-reported Quality of Life (QOL) as Measured by the Supplemental QOL Questionnaire

This is a multivariate repeated measurement of CIPN with possibly variable cycles for every patient. The supplemental quality of life (QOL) subscale will be calculated by standard scoring algorithm and converted to 0-100 scale, where higher scores represent a higher quality of life. Rather than choosing the subscale at a fixed cycle of chemotherapy, we will adopt a summary measure, area under the curve (AUC) . This AUC will be prorated by the number of chemotherapy cycles patients received. (NCT01099449)
Timeframe: Up to 18 months

,,
Interventionscore on a scale (Mean)
DiarrheaConstipationStomach CrampingBowel ProblemsSwallowingNumbness in finger and toesTingling in finger and toes
Arm I86.790.192.889.191.283.478.9
Arm II86.288.890.688.587.681.876.5
Arm III84.588.089.484.686.780.076.3

Percentage of Patients Experiencing Grade 2+ and Grade 3+ Chronic Cumulative Neurotoxicity.

Grades are determined by the National Cancer Institute's Common Terminology Criteria for Adverse Events (NCI CTCAE version 4.0) and oxaliplatin-specific neurotoxicity scale, during and after chemotherapy. Higher grades symbolize greater severity of the adverse event. (NCT01099449)
Timeframe: Up to 18 months

,,
Interventionpercentage of patients (Number)
grade 2+grade 3+
Calcium Gluconate + Magnesium Sulfate (Pre and Post)42.77.7
Calcium Gluconate + Magnesium Sulfate (Pre), Placebo (Post)46.17.8
Placebo (Pre and Post)44.87.8

Percentage of Patients With Acute Neuropathy Associated With Oxaliplatin

This is the percent of patients who scored >=50 in all sequences of all cycles by arm for side effect Q1: Sensitivity to touching cold. This is a> repeated measurement of CIPN with possibly variable cycles for every patient. The CIPN subscale will be calculated by standard scoring algorithm and converted to 0-100 scale. Where 0 is no sensitivity and 100 is as bad as it can be. (NCT01099449)
Timeframe: Up to 18 months

,,
Interventionpercentage of patients (Number)
Cycle 1Cycle 2Cycle 3Cycle 4Cycle 5Cycle 6Cycle 7Cycle 8Cycle 9Cycle 10Cycle 11Cycle 12
Arm I102432343431353234292827
Arm II132733373337343437393945
Arm III142832363933343332303332

Time to Onset of Grade 2+ and Grade 3+ Chronic Cumulative Neurotoxicity and the Duration of the Chronic Cumulative Neurotoxicity During and After Chemotherapy

Time to onset of grade 2+ and grade 3+ chronic cumulative neurotoxicity, the duration of the chronic cumulative neurotoxicity during and after the adjuvant oxaliplatin-based chemotherapy. Grades are determined by the National Cancer Institute's Common Terminology Criteria for Adverse Events (NCI CTCAE version 4.0) and oxaliplatin-specific neurotoxicity scale, during and after chemotherapy. Higher grades symbolize greater severity of the adverse event. (NCT01099449)
Timeframe: Up to 18 months

,,
InterventionDays (Median)
Time to Grade 2 NeuropathyTime to Grade 3 Neuropathy
Calcium Gluconate + Magnesium Sulfate (Pre and Post)171NA
Calcium Gluconate + Magnesium Sulfate (Pre), Placebo (Post)171NA
Placebo (Pre and Post)173208

Median Progression-Free Survival (PFS)

Time in months from the start of study treatment to the date of first progression (PD) according to the RECIST criteria, or death due to any cause. PER RECIST, a PD is indicated when there is at least a 20% increase in the sum of the longest diameters from target lesions relative to the smallest sum recorded since treatment is initiated. Median PFS was estimated using a Kaplan-Meier curve, and is the time at which 50% of patients remain alive without disease progression. (NCT00447330)
Timeframe: 5 years from study start date

Interventionsurvival time in months (Median)
1- Capecitabine (Xeloda), Oxaliplatin and Bevacizumab (Avastin6.97

Median Survival

Time in months from the start of study treatment to date of death due to any cause. Median survival was estimated using a Kaplan-Meier curve and is the time point at which 50% of patients remain alive. (NCT00447330)
Timeframe: 5 years after study start date

Interventionsurvival time in months (Median)
1 - Capecitabine (Xeloda), Oxaliplatin and Bevacizumab (Avasti10.51

Response Rate

The proportion of patients for whom the best overall response is complete response (CR) or partial response (PR). A CR occurs when all lesions disappear; whereas, a PR is indicated when there is at least a 30% decrease in the sum of the longest diameters (LD) of the target lesion. A PD (progressive disese) occurs when there is at least a 20% increase in the sum of the LD relative to the smallest sum LD recorded since treatment is initiated. Disease is considered stable if there is no response and no PD. All patients were assigned a best response for inclusion in this calculation in accordance with the protocol. (NCT00447330)
Timeframe: Every 9 weeks for up to 1 year

Interventionpercentage of participants (Number)
1 - Capecitabine (Xeloda), Oxaliplatin and Bevacizumab (Avasti41.7

To Assess the Safety and Tolerability of the Combination of Bevacizumab, Oxaliplatin and Capecitabine in Patients With Previously Untreated Metastatic Esophagogastric Adenocarcinoma

Number of subjects who experienced an adverse event (NCT00447330)
Timeframe: Every 21 days

Interventionparticipants (Number)
1 - Capecitabine (Xeloda), Oxaliplatin and Bevacizumab (Avasti56

Trials

4 trials available for fluorouracil and Sensation Disorders

ArticleYear
Phase III randomized, placebo-controlled, double-blind study of intravenous calcium and magnesium to prevent oxaliplatin-induced sensory neurotoxicity (N08CB/Alliance).
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2014, Apr-01, Volume: 32, Issue:10

    Topics: Administration, Intravenous; Aged; Antineoplastic Combined Chemotherapy Protocols; Calcium; Cold Tem

2014
Phase I/II study of capecitabine plus oxaliplatin (XELOX) plus bevacizumab as first-line therapy in Japanese patients with metastatic colorectal cancer.
    Japanese journal of clinical oncology, 2010, Volume: 40, Issue:10

    Topics: Adult; Aged; Anorexia; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Com

2010
Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2000, Volume: 18, Issue:16

    Topics: Adenocarcinoma; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal

2000
Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2000, Volume: 18, Issue:16

    Topics: Adenocarcinoma; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal

2000
Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2000, Volume: 18, Issue:16

    Topics: Adenocarcinoma; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal

2000
Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2000, Volume: 18, Issue:16

    Topics: Adenocarcinoma; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal

2000
Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2000, Volume: 18, Issue:16

    Topics: Adenocarcinoma; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal

2000
Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2000, Volume: 18, Issue:16

    Topics: Adenocarcinoma; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal

2000
Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2000, Volume: 18, Issue:16

    Topics: Adenocarcinoma; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal

2000
Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2000, Volume: 18, Issue:16

    Topics: Adenocarcinoma; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal

2000
Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2000, Volume: 18, Issue:16

    Topics: Adenocarcinoma; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal

2000
Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2000, Volume: 18, Issue:16

    Topics: Adenocarcinoma; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal

2000
Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2000, Volume: 18, Issue:16

    Topics: Adenocarcinoma; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal

2000
Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2000, Volume: 18, Issue:16

    Topics: Adenocarcinoma; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal

2000
Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2000, Volume: 18, Issue:16

    Topics: Adenocarcinoma; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal

2000
Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2000, Volume: 18, Issue:16

    Topics: Adenocarcinoma; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal

2000
Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2000, Volume: 18, Issue:16

    Topics: Adenocarcinoma; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal

2000
Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2000, Volume: 18, Issue:16

    Topics: Adenocarcinoma; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal

2000
Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2000, Volume: 18, Issue:16

    Topics: Adenocarcinoma; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal

2000
Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2000, Volume: 18, Issue:16

    Topics: Adenocarcinoma; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal

2000
Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2000, Volume: 18, Issue:16

    Topics: Adenocarcinoma; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal

2000
Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2000, Volume: 18, Issue:16

    Topics: Adenocarcinoma; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal

2000
Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2000, Volume: 18, Issue:16

    Topics: Adenocarcinoma; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal

2000
Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2000, Volume: 18, Issue:16

    Topics: Adenocarcinoma; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal

2000
Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2000, Volume: 18, Issue:16

    Topics: Adenocarcinoma; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal

2000
Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2000, Volume: 18, Issue:16

    Topics: Adenocarcinoma; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal

2000
Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2000, Volume: 18, Issue:16

    Topics: Adenocarcinoma; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal

2000
Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2000, Volume: 18, Issue:16

    Topics: Adenocarcinoma; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal

2000
Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2000, Volume: 18, Issue:16

    Topics: Adenocarcinoma; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal

2000
Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2000, Volume: 18, Issue:16

    Topics: Adenocarcinoma; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal

2000
Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2000, Volume: 18, Issue:16

    Topics: Adenocarcinoma; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal

2000
Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2000, Volume: 18, Issue:16

    Topics: Adenocarcinoma; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal

2000
Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2000, Volume: 18, Issue:16

    Topics: Adenocarcinoma; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal

2000
Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2000, Volume: 18, Issue:16

    Topics: Adenocarcinoma; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal

2000
Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2000, Volume: 18, Issue:16

    Topics: Adenocarcinoma; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal

2000
Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2000, Volume: 18, Issue:16

    Topics: Adenocarcinoma; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal

2000
Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2000, Volume: 18, Issue:16

    Topics: Adenocarcinoma; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal

2000
Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2000, Volume: 18, Issue:16

    Topics: Adenocarcinoma; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal

2000
Dose escalation of CPT-11 in combination with oxaliplatin using an every two weeks schedule: a phase I study in advanced gastrointestinal cancer patients.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2000, Volume: 11, Issue:11

    Topics: Adult; Aged; Alopecia; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protoco

2000

Other Studies

3 other studies available for fluorouracil and Sensation Disorders

ArticleYear
[Analysis of a case of oxaliplatin - induced persistence sensory neuropathy].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2010, Volume: 37, Issue:3

    Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neopl

2010
Long-term neuropathy after oxaliplatin treatment: challenging the dictum of reversibility.
    The oncologist, 2011, Volume: 16, Issue:5

    Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; De

2011
Persistent pain, sensory disturbances and functional impairment after adjuvant chemotherapy for breast cancer: cyclophosphamide, epirubicin and fluorouracil compared with docetaxel + epirubicin and cyclophosphamide.
    Acta oncologica (Stockholm, Sweden), 2012, Volume: 51, Issue:8

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvan

2012